ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock & Full Exercise of Underwriters’ Option to Purc...
November 30 2018 - 3:05PM
Business Wire
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system (CNS) disorders, today announced the closing of its
previously announced underwritten public offering of 18,602,941
shares of its common stock, including 2,426,470 shares of common
stock sold pursuant to the underwriters’ full exercise of their
option to purchase additional shares, at a public offering price of
$17.00 per share. The gross proceeds from the offering to ACADIA,
before deducting underwriting discounts and commissions and other
estimated offering expenses payable by ACADIA, are approximately
$316.2 million.
BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs
& Co. LLC acted as the joint book-running managers for the
offering. Cowen and Company, LLC acted as lead manager and Cantor
Fitzgerald & Co., JMP Securities LLC and Needham & Company,
LLC acted as co-managers for the offering.
The shares of common stock described above were offered by
ACADIA pursuant to a shelf registration statement filed by ACADIA
with the Securities and Exchange Commission (SEC) that became
automatically effective upon filing. A final prospectus supplement
and accompanying prospectus related to the offering were filed with
the SEC and are available on the SEC’s website located at
http://www.sec.gov. Copies of the final prospectus supplement and
the accompanying prospectus related to this offering may be
obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College
Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus
Department, Email: dg.prospectus_requests@baml.com, or from J.P.
Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866)
803-9204, or by email to: prospectus-eq_fi@jpmchase.com, or from
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, or by telephone at (866) 471-2526,
or by email to: prospectus-ny@nyemail.gs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About ACADIA PharmaceuticalsACADIA is a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system disorders. ACADIA has developed and is
commercializing the first and only medicine approved for the
treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. In addition, ACADIA has ongoing
clinical development efforts in additional areas with significant
unmet need, including dementia-related psychosis, schizophrenia
inadequate response, schizophrenia-negative symptoms, major
depressive disorder, and Rett syndrome.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181130005481/en/
Investor Contact:ACADIA Pharmaceuticals Inc.Elena Ridloff,
CFA(858) 558-2871ir@acadia-pharm.com
Media Contact:ACADIA Pharmaceuticals Inc.Maurissa Messier(858)
768-6068media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024